Elevating Our Communities With Every Interaction

Velocity is the world's leading integrated site organization.

Sponsors and CROs trust Velocity to deliver high-quality clinical trial data and patient care with unprecedented efficiency.

Simplify everything from site selection to study close-out

Velocity unifies operational processes to provide world-class sites, reliable enrollment, and predictably high performance for your trials.

Research sites across the U.S. and Europe
+
Investigators with diverse experience
+
Clinical trials conducted since 1986
treatment
mother-and-child-2
Hallandale
caring african medical nurse comforting senior patient in office
Velocity-team-office

The right sites.
The right investigators.
The right partner for you.

Strategically located to give you access to diverse specialty populations, Velocity's sites are supported by next-gen technologies and patient engagement capabilities. Welcome to recruitment and retention reimagined.

Scale for a purpose: Supporting research programs worldwide

From the leading pharma companies, to the most pioneering biotech startups, Velocity supports those who are exploring new frontiers in human health.

Whether you’re ready to conduct a single-site study or a complex, high-volume clinical trial, contact Velocity.

News

Paul Evans Featured in Business North Carolina Article on AI in the State’s Clinical Research Industry

September 5, 2024

Paul Evans was recently featured in a Business North Carolina article discussing the emerging impact of artificial intelligence on North Carolina’s clinical research industry. As Paul notes, “Our industry is … Read more

Drs. Essink and Overcash Author Article Featured in Nature Communications for Moderna COVE Study

August 30, 2024

Brandon Essink, MD, CPI, and J. Scott Overcash, MD, were authors of a recent Nature Communications article, “Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and … Read more

VISION Reaches $2 Million in Patient Stipends Paid Globally

August 22, 2024

Since launching in-app stipend payments, Velocity has paid more than $2 million to patients globally through VISION. The mobile app has also contributed to more than 2,500 patient randomizations, empowering … Read more

Kris Kowdley, MD, Supported Research Leading to Accelerated FDA Approval of Gilead’s Livdelzi® for Primary Biliary Cholangitis

August 15, 2024

Another milestone for patients with primary biliary cholangitis (PBC) — Gilead’s Livdelzi® (seladelpar) has received accelerated FDA approval as a second-line treatment for PBC. Kris Kowdley, MD, AGAF, FAASLD, FACP, … Read more

Quality. Continuity. Velocity.